Intraocular mitomycin C use in the treatment and prophylaxis of proliferative vitreoretinopathy in severe traumatic retinal detachments
Citation
Gürelik G, Sül S, Üçgül AY. Intraocular mitomycin C use in the treatment and prophylaxis of proliferative vitreoretinopathy in severe traumatic retinal detachments. Eur J Ophthalmol. 2021 Nov;31(6):3284-3293. doi: 10.1177/1120672120976038. Epub 2020 Nov 24. PMID: 33233948.Abstract
Purpose: To evaluate the anatomic and visual outcomes of a new intraocular mitomycin c (MMC) application technique
in the treatment of severe traumatic retinal detachment (RD) with advance proliferative vitreoretinopathy (PVR).
Methods: The records of 15 eyes of 14 patients who underwent vitreoretinal surgery and intraoperative MMC
application were reviewed retrospectively.
Surgical technique: After performing complicated vitreoretinal surgical procedures (Pars plana vitrectomy, PVR
membrane stripping, large retinotomy/retinectomies and intraocular foreign body removal if found etc. . .) retina was
attached with perfluorocarbon liquid (PFCL) and partial fluid-air exchange. Endolaser was performed. PFCL was removed
to the posterior borders of retinochoroidal wounds, breaks or retinectomy sites. The remaining PFCL was enough to
cover and prevent MMC contact with the posterior vital structures including optic disc, macula and underlying RPE and
major vascular arcades. Ciliary epithelium and other anterior segment structures were protected from MMC contact
with the use of air in the rest of the eye. Then, a 10µg/mL concentrated MMC solution was carefully injected above the
PFCL bubble until it covered PVR or potential areas of PVR development and removed after 60 s. Finally, the remaining
PFCL was removed and all eyes were filled with silicone oil. The patients were followed at least 6months after silicone
oil removal. Visual and anatomic outcomes were determined during follow-up period.
Results: The mean follow-up time was 19.6±6months (range 12–27months). About 100% retinal attachment was
achieved with one vitreoretinal surgery during the follow-up period. PVR was not detected around the retinal breaks
or retinotomy sites in any eye. Limited macular epiretinal membrane was detected in two eyes and subsequently peeled
during silicone oil removal. Preoperative visual acuities were hand motions in seven eyes and light perception in eight
eyes. Nine of 15 eyes had a visual acuity of ⩾0.1 during the follow-up period. The mean preoperative visual acuity was
logMAR 2.16±0.15 and postoperative visual acuity was 0.80±0.50 (p=0.001). There were no additional complications
related to intraoperative MMC use during follow-up period.
Conclusion: Temporary intraocular MMC use in vitreoretinal surgery yielded good anatomic and visual outcomes after
the treatment of traumatic RDs with PVR or those with high risk of PVR development. Furthermore, MMC application
appeared to prevent further PVR development after vitreoretinal surgery